July 24, 2012
/PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the appointment of Dr. Stephen Newman to its Board of Directors. Dr.
is the former Vice Chairman and Chief Operating Officer of Tenet Healthcare Corporation (THC), a health care delivery and services company, until his retirement in
's extensive leadership and experience, ranging from medical practitioner to COO of a major health care delivery system operating several dozen hospitals and providing services to hundreds of institutions, brings tremendous insight and value to Optimer's Board, particularly in these early stages of introducing DIFICID to the health care system," said Pedro Lichtinger, President and CEO of Optimer.
, 62, most recently served as Vice Chairman and Chief Operating Officer of Tenet Healthcare Corporation until his retirement in
joined Tenet in
and held various positions of increasing responsibility before eventually becoming COO, including Chief Executive Officer for Tenet's
region. Before joining Tenet, Dr.
held executive positions at
/HCA Inc. from
and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in
. Prior to 1990, Dr.
served as Associate Professor of Pediatrics and Medicine at
Wright State University
School of Medicine and as Director of Gastroenterology and Nutrition Support at Children's Medical Center in
, Ohio. Dr.
recently completed a five-year term on the Board of Directors of the Federation of American Hospitals and presently serves on the Federal Reserve Bank of
's Labor Education and Healthcare Advisory Committee. Dr.
holds a bachelor's degree from
, an M.B.A. from
and a medical degree from the
University of Tennessee
. He completed his internship, residency and fellowship at
Emory University School of Medicine
also completed the Advanced Management Program at the
University of Pennsylvania
's Wharton School of Business.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of
-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The Company is exploring marketing authorization in other parts of the world where
has emerged as a serious health problem. Additional information can be found at
Optimer Pharmaceuticals, Inc.
, VP of Investor Relations and Corporate Communications858-964-3418
Jason I. Spark
, Senior Vice President619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.